HHS Nominee Tom Price Grilled in Confirmation Hearing

Price was asked about alleged conflicts of interest, whether he supports Medicare negotiating drug prices, and how he intends to replace the Affordable Care Act.

Written byJoshua A. Krisch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, MARK TAYLORRepresentative Tom Price (R-GA), an orthopedic surgeon and president-elect Donald Trump’s choice to lead the Department of Health and Human Services, faced a contentious senate hearing on Wednesday (January 18).

In response to calls to repeal the Affordable Care Act before Congress can enact a plan to replace it—an idea once floated by Trump himself—Senator Patty Murray (D-WA) bluntly told Price that she had “serious concerns about your qualifications and plans for the department you hope to lead,” the Washington Post reported. “It’s like being asked to jump out of an airplane without a parachute and saying, ‘Trust us, we will build a parachute,’” added Senator Sheldon Whitehouse (D-RI).

Democrats asked Price whether he would support empowering Medicare to negotiate prices directly with drug companies, according to STAT—a position that Trump has championed, but that the GOP strongly opposes. “Will you work with us so that Medicare can negotiate prices?” asked Senator Bernie Sanders (D-VT). ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies